These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 21864627)

  • 1. Preparing for introduction of a dengue vaccine: recommendations from the 1st Dengue v2V Asia-Pacific Meeting.
    Lam SK; Burke D; Capeding MR; Chong CK; Coudeville L; Farrar J; Gubler D; Hadinegoro SR; Hanna J; Lang J; Lee HL; Leo YS; Luong CQ; Mahoney R; McBride J; Mendez-Galvan J; Ng LC; Nimmannitya S; Ooi EE; Shepard D; Smit J; Teyssou R; Thomas L; Torresi J; Vasconcelos P; Wirawan DN; Yoksan S
    Vaccine; 2011 Nov; 29(51):9417-22. PubMed ID: 21864627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Dengue fever: from disease to vaccination].
    Teyssou R
    Med Trop (Mars); 2009 Aug; 69(4):333-4. PubMed ID: 19725380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preparing for dengue vaccine introduction in ASEAN countries: recommendations from the first ADVA regional workshop.
    Thisyakorn U; Capeding MR; Goh DY; Hadinegoro SR; Ismail Z; Tantawichien T; Yoksan S; Pang T
    Expert Rev Vaccines; 2014 May; 13(5):581-7. PubMed ID: 24702301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Review of dengue virus and the development of a vaccine.
    Murrell S; Wu SC; Butler M
    Biotechnol Adv; 2011; 29(2):239-47. PubMed ID: 21146601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention and control of dengue-the light at the end of the tunnel.
    Pang T; Mak TK; Gubler DJ
    Lancet Infect Dis; 2017 Mar; 17(3):e79-e87. PubMed ID: 28185870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dengue vaccines for travelers.
    Wilder-Smith A; Deen JL
    Expert Rev Vaccines; 2008 Jul; 7(5):569-78. PubMed ID: 18564012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Challenges in reducing dengue burden; diagnostics, control measures and vaccines.
    Lam SK
    Expert Rev Vaccines; 2013 Sep; 12(9):995-1010. PubMed ID: 24053394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implementing rotavirus vaccination in Asia.
    Santosham M; Nelson EA; Bresee JS
    Vaccine; 2007 Nov; 25(44):7711-6. PubMed ID: 17881099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Points for Consideration for dengue vaccine introduction - recommendations by the Dengue Vaccine Initiative.
    Lim JK; Lee YS; Wilder-Smith A; Thiry G; Mahoney R; Yoon IK
    Expert Rev Vaccines; 2016; 15(4):529-38. PubMed ID: 26651238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dengue v2V--new global initiative supporting transition from vaccine to vaccination.
    Lam SK
    Vaccine; 2010 Feb; 28(9):2060-1. PubMed ID: 20045098
    [No Abstract]   [Full Text] [Related]  

  • 11. Updated recommendations of the International Dengue Initiative expert group for CYD-TDV vaccine implementation in Latin America.
    Torres JR; Falleiros-Arlant LH; Gessner BD; Delrieu I; Avila-Aguero ML; Giambernardino HIG; Mascareñas A; Brea J; Torres CN; Castellanos-Martinez JM
    Vaccine; 2019 Oct; 37(43):6291-6298. PubMed ID: 31515144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current issues in dengue vaccination.
    Thomas SJ; Endy TP
    Curr Opin Infect Dis; 2013 Oct; 26(5):429-34. PubMed ID: 23963259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimating the public health importance of the CYD-tetravalent dengue vaccine: Vaccine preventable disease incidence and numbers needed to vaccinate.
    Gessner BD; Wilder-Smith A
    Vaccine; 2016 Apr; 34(20):2397-401. PubMed ID: 27055020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dengue vaccine: opportunities and challenges.
    Hatch S; Mathew A; Rothman A
    IDrugs; 2008 Jan; 11(1):42-5. PubMed ID: 18175262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective human trials with dengue virus vaccines and the NS1 antigen production among vaccine recipients.
    Arya SC; Agarwal N
    Hum Vaccin; 2011 Dec; 7(12):1394. PubMed ID: 22108041
    [No Abstract]   [Full Text] [Related]  

  • 16. Current issues in the economics of vaccination against dengue.
    Tozan Y
    Expert Rev Vaccines; 2016; 15(4):519-28. PubMed ID: 26642099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dengue surveillance in preparation for field vaccine trials.
    Letson GW
    J Clin Virol; 2009 Oct; 46 Suppl 2():S10-2. PubMed ID: 19800559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of a pediatric dengue vaccine.
    Shepard DS; Suaya JA; Halstead SB; Nathan MB; Gubler DJ; Mahoney RT; Wang DN; Meltzer MI
    Vaccine; 2004 Mar; 22(9-10):1275-80. PubMed ID: 15003657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-Effectiveness of Dengue Vaccination Programs in Brazil.
    Shim E
    Am J Trop Med Hyg; 2017 May; 96(5):1227-1234. PubMed ID: 28500811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Financing dengue vaccine introduction in the Americas: challenges and opportunities.
    Constenla D; Clark S
    Expert Rev Vaccines; 2016; 15(4):547-59. PubMed ID: 26690087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.